Rob E Aarnoutse

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. ncbi request reprint Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands
    Antivir Ther 8:309-14. 2003
  2. ncbi request reprint Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers
    Rob E Aarnoutse
    Departments of Clinical Pharmacy and General Internal Medicine, Nijmegen University Centre for Infectious Diseases, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    Clin Pharmacol Ther 78:664-74. 2005
  3. pmc Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers
    R E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Clin Pharmacol 55:115-25. 2003
  4. ncbi request reprint Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Drugs 63:741-53. 2003
  5. doi request reprint Clinical experience with the combined use of lopinavir/ritonavir and rifampicin
    Rafaëlla Fa L'homme
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands
    AIDS 23:863-5. 2009
  6. ncbi request reprint A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study)
    David M Burger
    Department of Clinical Pharmacy, University Medical Center Nijmegen, The Netherlands
    Antivir Ther 8:455-61. 2003
  7. ncbi request reprint The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands
    Clin Pharmacol Ther 71:57-67. 2002
  8. ncbi request reprint Evaluation of antiretroviral drug measurements by an interlaboratory quality control program
    Jacqueline A H Droste
    Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 32:287-91. 2003
  9. pmc Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients
    Alma Tostmann
    Department of Respiratory Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 57:3208-13. 2013
  10. doi request reprint High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets
    Hanneke M J Nijland
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, The Netherlands
    AIDS 22:931-5. 2008

Detail Information

Publications32

  1. ncbi request reprint Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands
    Antivir Ther 8:309-14. 2003
    ..High indinavir Cmax values have been associated with indinavir-related nephrotoxicity...
  2. ncbi request reprint Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers
    Rob E Aarnoutse
    Departments of Clinical Pharmacy and General Internal Medicine, Nijmegen University Centre for Infectious Diseases, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    Clin Pharmacol Ther 78:664-74. 2005
    ..When applied in a therapeutic dose (600 mg twice daily), ritonavir also inhibits CYP2D6. The effect of low-dose ritonavir on CYP2D6 is unknown and was investigated in this study...
  3. pmc Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers
    R E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Clin Pharmacol 55:115-25. 2003
    ..This study was performed to evaluate the steady-state pharmacokinetics, food intake requirements and short-term tolerability of once-daily combinations of nelfinavir and low-dose ritonavir...
  4. ncbi request reprint Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Drugs 63:741-53. 2003
    ..Additional clinical trials are needed before routine TDM can be adopted as standard of care in the treatment of HIV infection...
  5. doi request reprint Clinical experience with the combined use of lopinavir/ritonavir and rifampicin
    Rafaëlla Fa L'homme
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands
    AIDS 23:863-5. 2009
    ..Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity...
  6. ncbi request reprint A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study)
    David M Burger
    Department of Clinical Pharmacy, University Medical Center Nijmegen, The Netherlands
    Antivir Ther 8:455-61. 2003
    ..A Phase II study was conducted to investigate the pharmacokinetics, and short-term safety and efficacy of an indinavir/ritonavir combination as part of a once-daily regimen...
  7. ncbi request reprint The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands
    Clin Pharmacol Ther 71:57-67. 2002
    ....
  8. ncbi request reprint Evaluation of antiretroviral drug measurements by an interlaboratory quality control program
    Jacqueline A H Droste
    Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 32:287-91. 2003
    ..This variability may have important implications for therapeutic drug monitoring of these drugs and for pharmacokinetic studies. Interlaboratory testing is useful to alert laboratories to previously undetected analytical problems...
  9. pmc Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients
    Alma Tostmann
    Department of Respiratory Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 57:3208-13. 2013
    ..The finding of low TB drug concentrations is concerning because low concentrations have been associated with worse treatment outcome in several other studies...
  10. doi request reprint High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets
    Hanneke M J Nijland
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, The Netherlands
    AIDS 22:931-5. 2008
    ..Our objective was to study the combined use of rifampicin and the newly introduced lopinavir/ritonavir tablets...
  11. doi request reprint Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania
    Jossy van den Boogaard
    Radboud University Nijmegen Medical Centre, University Centre for Chronic Diseases Dekkerswald, PO Box 66, 6560 AB, Groesbeek, The Netherlands
    J Antimicrob Chemother 66:1810-4. 2011
    ..We determined the rate of fluoroquinolone resistance in M. tuberculosis isolates obtained from Tanzanian patients and linked this to previous fluoroquinolone exposure and mycobacterial resistance to rifampicin and isoniazid...
  12. doi request reprint Xanthine oxidase inhibition by allopurinol increases in vitro pyrazinamide-induced hepatotoxicity in HepG2 cells
    Alma Tostmann
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Drug Chem Toxicol 33:325-8. 2010
    ....
  13. ncbi request reprint Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    AIDS 18:565-7. 2004
    ..The pharmacokinetic data suggest that indinavir/ritonavir plus efavirenz (without dose modifications) should be effective in treatment-naive patients, and this was supported by the treatment response of the participants...
  14. doi request reprint Therapeutic drug monitoring of voriconazole
    Roger J M Bruggemann
    Department of Clinical Pharmacy, Nijmegen University Centre for Infectious Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Ther Drug Monit 30:403-11. 2008
    ..We provide a summary of the problem so that further research can be conducted to address this are of clinical need...
  15. doi request reprint Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity
    Alma Tostmann
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Int J Antimicrob Agents 31:577-80. 2008
    ..In addition, pre-treatment with INH, HYD or RIF increases the in vitro toxicity of INH. These results give us greater insight into the development of ATDH...
  16. doi request reprint Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients
    Alma Tostmann
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Trop Med Int Health 15:268-72. 2010
    ..9% (95% CI 0.04-4.3%). It is encouraging to find a lower rate of antituberculosis drug-induced hepatotoxicity than one would expect based on the high prevalence of risk factors such as HIV and hepatitis B...
  17. pmc International interlaboratory quality control program for measurement of antiretroviral drugs in plasma
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 46:884-6. 2002
    ..The results demonstrate the need for and utility of an ongoing quality control program in this area of bioanalysis...
  18. ncbi request reprint Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations
    David M Burger
    Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands
    Ther Drug Monit 25:73-80. 2003
    ..014). Virologic failure of nelfinavir-containing triple therapy can be explained, to a large extent, by low plasma levels of nelfinavir...
  19. ncbi request reprint Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance
    Patricia W H Hugen
    Department of Clinical Pharmacy, University Medical Nijmegen, Nijmegen, The Netherlands
    Ther Drug Monit 24:579-87. 2002
    ..In the absence of a gold standard for measuring compliance and to avoid complex techniques, measuring plasma concentrations may be an objective and easy way to check noncompliance...
  20. doi request reprint Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
    Jakko van Ingen
    University Center for Chronic Diseases Dekkerswald and Department of Pulmonary Diseases, Radboud University Nijmegen MedicalCenter, Nijmegen, The Netherlands
    Clin Infect Dis 52:e194-9. 2011
    ..The reduced cost and the lack of evidence of toxicity at higher daily doses remove the other arguments. To optimize tuberculosis treatment, the clinical value of higher doses of rifampicin should be tested in clinical trials...
  21. doi request reprint The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out?
    Jossy van den Boogaard
    University Centre for Chronic Diseases Dekkerswald, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Trop Med Int Health 16:693-8. 2011
    ....
  22. ncbi request reprint Pros and cons of therapeutic drug monitoring of antiretroviral agents
    David M Burger
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands
    Curr Opin Infect Dis 15:17-22. 2002
    ..In addition, therapeutic drug monitoring may be used as a direct and objective instrument to measure non-adherence. This review describes possibilities and limitations of therapeutic drug monitoring in HIV treatment...
  23. doi request reprint An exploration of patient perceptions of adherence to tuberculosis treatment in Tanzania
    Jossy van den Boogaard
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Qual Health Res 22:835-45. 2012
    ..Our preliminary adherence behavior model should be validated in larger, nonadherent patient populations and evaluated for its applicability to the development of adherence-promoting strategies...
  24. doi request reprint Sale of fluoroquinolones in northern Tanzania: a potential threat for fluoroquinolone use in tuberculosis treatment
    Jossy van den Boogaard
    Radboud University Nijmegen Medical Centre, The Netherlands
    J Antimicrob Chemother 65:145-7. 2010
    ..The current study evaluates the sale of fluoroquinolones (among other antibacterials) in Moshi, Tanzania, a country with one of the highest burdens of TB in the world...
  25. pmc International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations
    Roger J M Bruggemann
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 53:303-5. 2009
    ..The results demonstrate the need for and utility of an ongoing proficiency testing program to further improve the analytical methods for routine patient management and clinical research...
  26. ncbi request reprint Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes
    Hanneke M J Nijland
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Infect Dis 43:848-54. 2006
    ..Because lower concentrations of anti-TB drugs may be a contributing factor, we compared the pharmacokinetics of rifampicin in patients with TB, with and without DM...
  27. doi request reprint Effect of mild diarrhea on tacrolimus exposure
    Gerben A J van Boekel
    Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Transplantation 94:763-7. 2012
    ..The aim was to assess the degree of unnoticed tacrolimus overexposure in renal transplant patients with mild diarrhea while on treatment with tacrolimus and MMF...
  28. ncbi request reprint Antituberculosis drug-induced hepatotoxicity: concise up-to-date review
    Alma Tostmann
    Department of Pulmonary Diseases, and University Lung Center Dekkerswald, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    J Gastroenterol Hepatol 23:192-202. 2008
    ..Priorities for future studies include basic studies to elucidate the mechanism of antituberculosis drug-induced hepatotoxicity, genetic risk factor studies and the development of shorter and safer tuberculosis drug regimens...
  29. pmc Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients
    Rovina Ruslami
    Department of Pharmacology, Medical Faculty, University of Padjadjaran, Bandung, Indonesia
    Antimicrob Agents Chemother 51:2546-51. 2007
    ..Follow-up studies are warranted to assess whether high-dose rifampin may enable shortening of TB treatment...
  30. ncbi request reprint The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID
    David M Burger
    J Acquir Immune Defic Syndr 35:97-8. 2004
  31. ncbi request reprint Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 34:134-9. 2003
    ....
  32. ncbi request reprint Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?
    David M Burger
    J Acquir Immune Defic Syndr 29:101-2. 2002